KaloBios Pharmaceuticals, Inc.

KaloBios Pharmaceuticals, Inc. is a publicly traded company as of February 2013.
Below is PrivCo's archived report for KaloBios Pharmaceuticals, Inc.

What's included with your PrivCo Report Purchase:

Next Actions on KaloBios Pharmaceuticals, Inc.:

Business Summary

KaloBios Pharmaceuticals, Inc. is a privately-held, venture capital backed biopharmaceutical company. Founded in 2001, KaloBios Pharmaceuticals specializes in developing human antibody therapeutic candidates spanning the fields of autoimmunity, anti-infectives, and cancer therapeutics. Founded in 2001, KaloBios Pharmaceuticals is headquartered in South San Francisco, California.

Jump to KaloBios Pharmaceuticals, Inc.: Detailed Business Description for more details on KaloBios Pharmaceuticals, Inc. products and services, financial structure, KaloBios Pharmaceuticals, Inc. major business events, and more.

Overview & Corporate Organization

Basic Information

Company Tags:	VC Backed
Year Founded:	2001
Fiscal Year End:	12/31
1YR Revenue Growth Rate:	View %
City:	South San Francisco
State/Province:	California
Country:	United States
Phone:	View
Website:	www.kalobios.com

Industry Information

Industry Codes

PICS™:	1500107™
NAICS:	View
SIC:	View

PrivCo Industries (Sector > Industry > Sub-Industry)

Technology > Biotechnology > Biotherapeutics

The PrivCo Industry Classification System™ (PICS) is our proprietary, modernized industry classification system, geared especially toward privately-held companies and including newer emerging sub-industries that are not reflected in other outdated industry classification systems, such as SIC and NAICS.

Ownership

PrivCo's Ownership table displays who owns KaloBios Pharmaceuticals, Inc., including owner name, each type of owner (whether family, individual, private equity firm, etc.)

Owner Name	Type of Owner	% Ownership Stake
View	View	View
View	View	View
View	View	View
View	View	View
View	View	View
View	View	View
View	View	View
View	View
View	View

Charts, Financials, and Statistics (Table Format)

Below are KaloBios Pharmaceuticals, Inc. financials and other business metrics displayed in table format.
Copy & Paste Financials Into Spreadsheet or

Export All KaloBios Pharmaceuticals, Inc. Financials To Excel

All data before 2006 is completely free to view! To access data from 2006 onward:

Worldwide
United States
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Washington, D.C.
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Puerto Rico
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming
Canada
Alberta
British Columbia
Manitoba
New Brunswick
Newfoundland and Labrador
Northwest Territories
Nova Scotia
Nunavut
Ontario
Prince Edward Island
Quebec
Saskatchewan
Yukon
Europe (all countries)
UK
Germany
France
Italy
Europe (excluding UK)
Asia-Pacific (all countries)
Australia
China
Hong Kong
India
South Korea
Taiwan
Japan
Asia-Pacific (excluding India)
Latin America (all countries)
Middle East & Africa (all countries)

Get Full Access To This Report	or	Upgrade to PrivCo Premium
$99 Single Company Access		Instant Full Site-Wide Access *Currently 50% Off Until May. 31!*

Income Statement	2011	2010	2009
Revenue from Contract	View	View	View
General and Administrative Expenses	View	View	View
Research and Development Expense (Excluding In - Process)	View	View	View
Total Operating Expenses excluding costs	View	View	View
Operating Income/(Loss)	View	View	View
Interest Income	View	View	View
Non-operating Income/(Expense) - Other	View	View	View
Income/(Loss) from Continuing Operations Before Income Taxes	View	View	View
Provision for Income Taxes	View	View	View
Net Income (Loss)	View	View	View
Comprehensive Income Unrealized Available For Sale for Investments	View	View	View
Total Comprehensive Net Income	View	View	View

Balance Sheet	2011	2010
Cash and Cash Equivalents	View	View
Current Marketable Securities	View	View
Current Restricted Cash		View
Net Contract Receivables	View	View
Accrued Interest	View	View
Prepaid Expenses	View	View
Current Assets	View	View
Net Property, Plant and Equipment	View	View
Net Intangible Assets	View	View
Restricted Cash	View	View
Assets	View	View
Accounts Payable	View	View
Accrued Expenses - Other	View	View
Accrued Salaries	View	View
Other Accrued Expenses	View
Current Deferred/(Unearned) Revenue	View	View
Current Other Deferred Liability Charges	View	View
Current Liabilities	View	View
Notes Payable - Long-Term	View
Deferred/(Unearned) Revenue - Long-Term		View
Other Deferred Long Term Liability Charges	View	View
Noncurrent Other Liabilities	View	View
Liabilities	View	View
Convertible Preferred Stock Obligations	View	View
Common Stock - Value (Excluding Additional Paid in Capital)	View	View
Additional Paid in Capital	View	View
Retained Earnings	View	View
Other Accumulated Comprehensive Income, Net of Tax Effect	View	View
Stockholders' Equity	View	View
Liabilities and Stockholders' Equity	View	View

Cash Flow Statement	2011	2010
Operating Activities Beginning Net Income	View	View
Adjustment Amortization - Intangibles (Non-Productive)	View	View
Amortization	View	View
Depreciation and Amortization	View	View
Gain/(Loss) on Sale/Retirement of Property, Plant and Equipment	View	View
Adjustment for Equity Based Compensation Expense	View	View
Other Adjustments to Common Stockholders' Net Income - Increase/(Decrease)	View	View
Change Other Receivable	View	View
Change Prepaid Expenses Other Current Assets	View	View
Increase/(Decrease) in Deferred Charges	View	View
Increase/(Decrease) in Accounts Payable	View	View
Change Other Accrued Expenses	View	View
Increase/(Decrease) in Accrued Expenses	View	View
Increase/(Decrease) in Unearned Premiums	View	View
Increase/(Decrease) in Other Non-operating Liabilities	View	View
Net Cash Flows Provided By/(Used In) Operating Activities	View	View
Purchase of Property, Plant and Equipment	View	View
Purchase of Marketable Securities	View	View
Proceeds Sale Marketable Securities	View	View
Increase Decrease Restricted Funds	View	View
Proceeds from Sale of Property, Plant and Equipment	View	View
Net Cash Flows Provided By/(Used In) Investing Activities	View	View
Proceeds from Issuance of Common Stock	View	View
Proceeds from Issuance of Convertible Preferred Stock	View	View
Repurchase of Common Stock	View	View
Stock Issuance Costs	View	View
Net Cash Flows Provided By/(Used In) Financing Activities	View	View
Increase/(Decrease) in Cash and Cash Equivalents	View	View
Cash and cash equivalents at the beginning of the year	View	View
Total Cash and cash equivalents at the end of the year	View	View

Financial Notes:
*	KaloBios Pharmaceuticals, Inc. fiscal year end: 12/31

	Date	Investor	Round	Investor Type
	Jun. 2003	Alloy Ventures, Inc.	A	Venture Capital
	Jun. 2003	Sofinnova Ventures, Inc.	A	Venture Capital
Details		Total Round A $4,000,000
	Jun. 2004	GBS Venture Partners Ltd.	B	Venture Capital
	Jun. 2004	Alloy Ventures, Inc.	B	Venture Capital
	Jun. 2004	Bio*One Capital Pte Ltd	B	Private Equity
	Jun. 2004	MPM Capital	B	Venture Capital
	Jun. 2004	Lotus BioScience Ventures	B	Venture Capital
	Jun. 2004	5AM Ventures	B	Venture Capital
	Jun. 2004	Sofinnova Ventures, Inc.	B	Venture Capital
Details		Total Round B $10,590,000
	Mar. 2005	GBS Venture Partners Ltd.	B	Venture Capital
	Mar. 2005	5AM Ventures	B	Venture Capital
	Mar. 2005	Sofinnova Ventures, Inc.	B	Venture Capital
	Mar. 2005	MPM Capital	B	Venture Capital
Details		Total Round B $15,800,000
	Jul. 2007	View	C	Venture Capital
	Jul. 2007	View	C	Venture Capital
	Jul. 2007	View	C	Venture Capital
	Jul. 2007	View	C	Private Equity
	Jul. 2007	View	C	Venture Capital
	Jul. 2007	View	C	Private Equity
	Jul. 2007	View	C	Venture Capital
	Jul. 2007	View	C	Venture Capital
Details		Total Round C View
	Dec. 2008	View	D	Venture Capital
	Dec. 2008	View	D	Venture Capital
	Dec. 2008	View	D	Venture Capital
	Dec. 2008	View	D	Venture Capital
	Dec. 2008	View	D	Venture Capital
	Dec. 2008	View	D	Venture Capital
	Dec. 2008	View	D
Details		Total Round D View
	May. 2012	View	E	Corporate
Details		Total Round E View
		Total of Funding Shown Above View

	Date	Deal Type	Action	Resulting Status	Valuation	Amount Raised	Public Ticker
Details	Feb. 2013	View	View	View¹	View	View	View

1	8,250,000 shares priced at $8....Read More →
	Full-length notes are available with Single Report Access or PrivCo Premium Subscription.

Choose Region(s):
Or Enter Location (US, CAN, UK): within miles
Annual Revenues search is available on PrivCo Premium. Upgrade to PrivCo Premium Subscription Annual Revenues:
Industry:
Go to Advanced Search

KaloBios Pharmaceuticals, Inc.

Business Summary

Overview & Corporate Organization

Basic Information

Industry Information

Industry Codes

PrivCo Industries (Sector > Industry > Sub-Industry)

Ownership

Charts, Financials, and Statistics (Table Format)

Charts, Financials, and Statistics (Graphs)

KaloBios Pharmaceuticals, Inc. Revenue from Contract ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. General and Administrative Expenses ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Research and Development Expense (Excluding In - Process) ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Total Operating Expenses excluding costs ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Operating Income/(Loss) ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Interest Income ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Non-operating Income/(Expense) - Other ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Income/(Loss) from Continuing Operations Before Income Taxes ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Provision for Income Taxes ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Net Income (Loss) ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Comprehensive Income Unrealized Available For Sale for Investments ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Total Comprehensive Net Income ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Cash and Cash Equivalents ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Current Marketable Securities ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Net Contract Receivables ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Accrued Interest ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Prepaid Expenses ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Current Assets ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Net Property, Plant and Equipment ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Net Intangible Assets ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Restricted Cash ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Assets ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Accounts Payable ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Accrued Expenses - Other ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Accrued Salaries ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Current Deferred/(Unearned) Revenue ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Current Other Deferred Liability Charges ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Current Liabilities ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Other Deferred Long Term Liability Charges ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Noncurrent Other Liabilities ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Liabilities ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Convertible Preferred Stock Obligations ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Common Stock - Value (Excluding Additional Paid in Capital) ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Additional Paid in Capital ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Retained Earnings ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Other Accumulated Comprehensive Income, Net of Tax Effect ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Stockholders' Equity ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Liabilities and Stockholders' Equity ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Operating Activities Beginning Net Income ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Adjustment Amortization - Intangibles (Non-Productive) ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Amortization ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Depreciation and Amortization ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Gain/(Loss) on Sale/Retirement of Property, Plant and Equipment ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Adjustment for Equity Based Compensation Expense ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Other Adjustments to Common Stockholders' Net Income - Increase/(Decrease) ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Change Other Receivable ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Change Prepaid Expenses Other Current Assets ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Increase/(Decrease) in Deferred Charges ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Increase/(Decrease) in Accounts Payable ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Change Other Accrued Expenses ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Increase/(Decrease) in Accrued Expenses ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Increase/(Decrease) in Unearned Premiums ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Increase/(Decrease) in Other Non-operating Liabilities ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Net Cash Flows Provided By/(Used In) Operating Activities ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Purchase of Property, Plant and Equipment ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Purchase of Marketable Securities ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Proceeds Sale Marketable Securities ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Increase Decrease Restricted Funds ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Net Cash Flows Provided By/(Used In) Investing Activities ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Proceeds from Issuance of Common Stock ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Net Cash Flows Provided By/(Used In) Financing Activities ($): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Increase/(Decrease) in Cash and Cash Equivalents ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Cash and cash equivalents at the beginning of the year ($ MM): (Displayed as graph)

KaloBios Pharmaceuticals, Inc. Total Cash and cash equivalents at the end of the year ($ MM): (Displayed as graph)

VC/Funding Activity

Public / Private History (PPH™)

Detailed Business Description: KaloBios Pharmaceuticals, Inc.

Supplemental Resources

PrivCo Private Deals Newsletter.It's FREE!

Who We Serve

KaloBios Pharmaceuticals, Inc. Revenue from Contract ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. General and Administrative Expenses ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Research and Development Expense (Excluding In - Process) ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Total Operating Expenses excluding costs ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Operating Income/(Loss) ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Interest Income ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Non-operating Income/(Expense) - Other ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Income/(Loss) from Continuing Operations Before Income Taxes ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Provision for Income Taxes ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Net Income (Loss) ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Comprehensive Income Unrealized Available For Sale for Investments ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Total Comprehensive Net Income ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Cash and Cash Equivalents ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Current Marketable Securities ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Net Contract Receivables ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Accrued Interest ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Prepaid Expenses ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Current Assets ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Net Property, Plant and Equipment ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Net Intangible Assets ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Restricted Cash ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Assets ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Accounts Payable ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Accrued Expenses - Other ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Accrued Salaries ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Current Deferred/(Unearned) Revenue ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Current Other Deferred Liability Charges ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Current Liabilities ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Other Deferred Long Term Liability Charges ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Noncurrent Other Liabilities ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Liabilities ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Convertible Preferred Stock Obligations ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Common Stock - Value (Excluding Additional Paid in Capital) ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Additional Paid in Capital ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Retained Earnings ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Other Accumulated Comprehensive Income, Net of Tax Effect ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Stockholders' Equity ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Liabilities and Stockholders' Equity ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Operating Activities Beginning Net Income ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Adjustment Amortization - Intangibles (Non-Productive) ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Amortization ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Depreciation and Amortization ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Gain/(Loss) on Sale/Retirement of Property, Plant and Equipment ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Adjustment for Equity Based Compensation Expense ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Other Adjustments to Common Stockholders' Net Income - Increase/(Decrease) ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Change Other Receivable ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Change Prepaid Expenses Other Current Assets ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Increase/(Decrease) in Deferred Charges ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Increase/(Decrease) in Accounts Payable ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Change Other Accrued Expenses ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Increase/(Decrease) in Accrued Expenses ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Increase/(Decrease) in Unearned Premiums ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Increase/(Decrease) in Other Non-operating Liabilities ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Net Cash Flows Provided By/(Used In) Operating Activities ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Purchase of Property, Plant and Equipment ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Purchase of Marketable Securities ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Proceeds Sale Marketable Securities ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Increase Decrease Restricted Funds ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Net Cash Flows Provided By/(Used In) Investing Activities ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Proceeds from Issuance of Common Stock ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Net Cash Flows Provided By/(Used In) Financing Activities ($):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Increase/(Decrease) in Cash and Cash Equivalents ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Cash and cash equivalents at the beginning of the year ($ MM):
(Displayed as graph)

KaloBios Pharmaceuticals, Inc. Total Cash and cash equivalents at the end of the year ($ MM):
(Displayed as graph)

PrivCo Private Deals Newsletter.
It's FREE!